Paris
Paris
The plant known as Paris, also referred to as "lily-of-the-valley," has not been traditionally used for medicinal purposes in any recorded practices. Scientific evidence is limited and primarily focuses on its use in managing equine dental conditions post-extraction rather than human health applications. Studies indicate that there may be a significant misclassification rate of primary biliary cholangitis (PBC) patients, which could impact treatment decisions; however, the evidence base for Paris itself remains inconclusive. There are no known drug interactions or major safety concerns associated with this plant.
- Best evidence
- D
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- Misclassification between clinical judgment and formal Paris II criteria occurs in about 20% of PBC patients, potentially affecting treatment decisions.
- The review summarizes current practices and materials for managing equine cheek tooth alveoli post-extraction but does not establish standardized protocols.
- The study found that using cefotaxime instead of ceftriaxone in Paris hospitals would increase carbon emissions, waste production, and costs.
- Children with MARS1-related pulmonary alveolar proteinosis show borderline to mild intellectual disability and significant deficits in adaptive behavior, despite methionine supplementation.
- The effectiveness of healthcare quality systems depends more on leadership commitment and workforce engagement than formal adoption alone, with mixed evidence for direct impacts on patient outcomes.
- SSM measurements during normal breathing showed better diagnostic accuracy for predicting oesophageal varices compared to breath-hold measurements.
Frequently asked questions
What is Paris?
Paris (Paris) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Paris?
6 sourced findings are recorded for Paris; the strongest carries evidence grade D. For example: Misclassification between clinical judgment and formal Paris II criteria occurs in about 20% of PBC patients, potentially affecting treatment decisions.
How strong is the evidence for Paris?
The strongest finding for Paris carries evidence grade D — preliminary or traditional. Grades run A (strongest) to D (preliminary or traditional).
Is Paris safe? What are the side effects?
No major safety issues are recorded for Paris in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Paris interact with medications?
No drug interactions are recorded for Paris in our sources. This does not rule them out — check with a pharmacist.
What are the common names of Paris?
Paris is also known as: Вороний глаз, Parisette.
Is Paris a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals. literature abstract metadata
- T2 Management of Equine Post-Extraction Cheek Tooth Alveoli: Application of Alveolar Plugs. literature abstract metadata
- T2 Healthcare Quality Systems: International Frameworks, Evaluation and Improvement Strategies. literature abstract metadata
- T2 Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting. literature abstract metadata
- T2 Neurodevelopmental Profile of Children With MARS1-Related Pulmonary Alveolar Proteinosis: A Cohort Study. literature abstract metadata
- T2 Impact of Breath Holding on Spleen Stiffness Measured by 100 Hz Vibration Controlled Transient Elastography. literature abstract metadata